HKG Epitherapeutics publishes new data on epiCervix test, showing ability to detect cervical cancer earlier than traditional screening methods
HKG Epitherapeutics (“HKG” or the “Company”), in collaboration with McGill University, announced that the International Journal of Cancer has published new data on the ability of the Company’s proprietary epiCervix test to detect cervical cancer in patients sooner compared to traditional screening methods, including manual laboratory cell examination from Papanicolaou (Pap) smears and human papillomavirus (HPV) testing.
HKG’s epiCervix test can detect cervical cancer at its earliest stages by looking at changes in four specific genes. Results from the study, which evaluated 800 women in Quebec, demonstrated the test’s accuracy in identifying women with both premalignant and malignant cells, including those who did not have their cancer detected through traditional screening methods. When cervical cancer is found early, doctors can treat it through immediate surgery, saving women from unnecessary medical procedures, anxiety and costs.
